BioSpace News Archive

VieMed’s clinically proven care model being deployed in Arizona to improve outcomes in patients with impaired respiratory function

Conformis, Inc. announced that it intends to offer shares of its common stock in an underwritten public offering.

Rolling BLA submission for AT-GAA planned for completion in Q2 and other global regulatory submissions for approval expected throughout 2021

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it has commenced an underwritten public offering of shares of its common stock.

ViewRay, Inc. (Nasdaq: VRAY) announced the appointment of Phil Spencer to its Board of Directors, effective February 9, 2021.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its fourth quarter 2020 financial results after the market closes on Thursday, February 25, 2021.

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming virtual SVB Leerink Global Healthcare Conference.

Infinity Pharmaceuticals, Inc., a clinical-stage biotechnology company developing eganelisib, an oral, immuno-oncology macrophage reprogramming therapeutic candidate, which is designed to address a fundamental biologic mechanism of immune suppression in cancer, announced that it has commenced an underwritten public offering of its common stock.

Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2020. Record fourth quarter revenue reflects a strong close to 2020: Revenue of $953 million, an increase of 20% compared to the third quarter of 2020 and $0.5 million higher compared to the prior year period

-Net Product Sales of $1 Billion in 2020, an Increase of 59 Percent Over 2019- -European Medicines Agency’s CHMP Adopted Positive Opinion Recommending Approval of TUKYSA for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer-